{"organizations": [], "uuid": "293b48a2de3e9a1e8d409fb6f979c2a2de81e214", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/esperion-thera-study/esperions-cholesterol-drug-safe-effective-in-new-late-stage-study-idUSL3N1SU4Q4", "country": "US", "domain_rank": 408, "title": "Esperion's cholesterol drug safe, effective in new late-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-23T16:16:00.000+03:00", "replies_count": 0, "uuid": "293b48a2de3e9a1e8d409fb6f979c2a2de81e214"}, "author": "", "url": "https://www.reuters.com/article/esperion-thera-study/esperions-cholesterol-drug-safe-effective-in-new-late-stage-study-idUSL3N1SU4Q4", "ord_in_thread": 0, "title": "Esperion's cholesterol drug safe, effective in new late-stage study", "locations": [], "entities": {"persons": [{"name": "manas mishra sai sachin ravikumar", "sentiment": "none"}], "locations": [], "organizations": [{"name": "esperion", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "esperion therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23, 2018 / 1:17 PM / Updated 20 minutes ago Esperion's cholesterol drug safe, effective in new late-stage study Reuters Staff 1 Min Read\nMay 23 (Reuters) - Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment’s efficacy.\nEsperion’s shares plunged some 30 percent on May 2 after analysts questioned the drug’s safety and effectiveness despite late-stage results showing that the treatment had met the main study goal.\nIn the new study, the treatment, bempedoic acid, met the main goal of reduction in low-density lipoprotein cholesterol levels when compared with a placebo.\nThe study results also showed that adverse muscle-related side effects were lower in patients taking Esperion’s treatment compared with those on a placebo.\nEsperion’s shares rose nearly 3 percent in premarket trading. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)", "external_links": [], "published": "2018-05-23T16:16:00.000+03:00", "crawled": "2018-05-23T16:33:37.005+03:00", "highlightTitle": ""}